DLL3 Expression among SCLC patients (Matterhorn)
Research type
Research Study
Full title
Prevalence of DLL3 expression among SCLC patients under real world conditions (MATTERHORN)
IRAS ID
247743
Contact name
John Gosney
Contact email
Sponsor organisation
AbbVie Ltd
Duration of Study in the UK
0 years, 8 months, 28 days
Research summary
Small cell lung cancer (SCLC) currently accounts for about 12% of lung cancers being diagnosed in the UK. Patients with SCLC who are treated with the current standard therapy initially respond well. In many patients the cancer will return leading to an average survival time of 14-20 months in patients with limited stage lung cancer (cancer in one lung) and 9-11 months in patients with extensive stage lung cancer (cancer in both lungs and other parts of the body). This represents a significant unmet medical need.
Delta-like protein 3 (DLL3) is a biomarker which can be expressed on the surface of cancer cells but is not expressed in normal tissues. However, exactly how and at what frequency DLL3 is expressed is not clearly understood.
This is a multi-centre, multi-country, non-interventional study, which will evaluate DLL3 biomarker expression and corresponding patients’ characteristics in archived SCLC tumour tissue samples. The aim of the study is to assess DLL3 expression from at least 1000 specimens.
Tumour tissue samples for SCLC patients at various stages of the disease, with a variety of different types of treatment will be analysed. Only specimens which have been archived for research will be used, and this study should not impact the treatment decisions of individual patients.
REC name
North West - Haydock Research Ethics Committee
REC reference
18/NW/0622
Date of REC Opinion
16 Aug 2018
REC opinion
Favourable Opinion